

PTO/SB/21 (01-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/626,681
	Filing Date	July 24, 2003
	First Named Inventor	Alanine
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21237

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks Documents A1, B1 - B14 and C1 - C21	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual	Dennis P. Tramaloni
Signature	
Date	August 27, 2003

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on this date <u>August 27, 2003</u>	
Typed or printed	Dennis P. Tramaloni
Signature	
Date	August 27, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventor(s) Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, ThomasLuebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge.

Group:

Serial No. 10/626,681, filed July 24, 2003
(Case Docket No. 21237)

Examiner:

For: BENZODIOXOLE DERIVATIVES

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
August 27, 2003

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.


Documents A1, B1-B14, and C1-C21 listed on Form PTO-1449 are enclosed.

Serial No. 10/626,681
Filed: July 24, 2003

Consideration of all the documents cited on Form PTO-1449 is requested.

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,



Attorney for Applicant(s)
Dennis P. Tramaloni
(Reg. No. 28,542)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-4475
Telefax: (973) 235-2363

133203



Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Application Number	10/626,681
				Filing Date	July 24, 2003
				First Name Inventor	Alanine
				Group Art Unit	
				Examiner Name	
Sheet	1	of	2	Attorney Docket Number	21237

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	A1	5,624,941		Barth, et. al.	04-29-1997

FOREIGN PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
	B1		EP658546		SANOFI-SYNTHELABO	06-21-1995
	B2		EP656354		SANOFI	06-07-1995
	B3		EP576357		SANOFI	06-07-1995
	B4		EP 0216831		BIGADAN A/S, HOJBOGARD BIOGASTEKNOLOGI	08-04-1987
	B5		WO0224630		ELI LILLY & CO.	03-28-2002
	B6		WO0015609		MIGNANI	03-23-2000
	B7		WO0164634		AVENTIS PHARMA S.A.	09-07-2001
	B8		WO0228346		AVENTIS PHARMA S.A.	04-11-2002
	B9		WO0164632		AVENTIS PHARMA S.A.	09-07-2001
	B10		WO0164633		AVENTIS PHARMA S.A.	09-07-2001
	B11		WO0132663		SANOFI-SYNTHELABO	05-10-2001
	B12		WO0046209		SANOFI-SYNTHELABO	08-10-2000
	B13		WO9719063		SANOFI	05-29-1997
	B14		WO0158869		BRISTOL-MYERS SQUIBB CO.	08-16-2001

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.



Substitute for form 1449A/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Application Number	10/626,681		
		Filing Date	July 24, 2003		
		First Name Inventor	Alanine		
		Group Art Unit			
		Examiner Name			
Sheet	2		2	Attorney Docket Number	21237

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	D. Shire, et. al, J. Biol. Chem. 270 (8) (1995) 3726-31	
	C2	S. Munro, et. al. Nature 365 (1993) 61-61	
	C3	Y. Gaoni, et. al. J. Am. Chem. Soc. 86 (1964) 16	
	C4	R. Mechoulam (Ed.) in "Cannabinoids as therapeutic Agents", (1986), pp. 1-20, CRC Pr	
	C5	E.M. Williamson, F. J. Evans, Drugs 60 (6) (2000) 1303-1314	
	C6	R. G. Pertwee, Curr. Med. Chem., 6 (8) (1999) 635-664	
	C7	W.A. Devane, et. al. Science 258 (1992) 1946-9	
	C8	V. Di Marzo, et. al., Trends in Neuroscience 21 (12) (1998) 521-8	
	C9	A.C. Porter, C.C. Felder, Pharmacol. Ther., 90 (1) (2001) 45-60	
	C10	C.M. Williams, T.C. Kirkham, Psychopharmacology 143 (3) (1999) 315-317	
	C11	C.C. Felder, et. al., Proc. Natl. Acad. Sci. USA 90 (16) (1993) 7656-7660	
	C12	G. Colombo, et. al., Life Sci. 63 (8) (1998) L113-PL117	
	C13	V. Di Marzo, et. al., Nature 410 (6830) 822-825	
	C14	F. Barth, et. al. "Cannabinoid antagonists: From research tools to potential new drugs", Abstracts of Papers, 222 nd ACS National Meeting, Chicago, IL, United States, August 26-30, 2001	
	C15	AAI; M. Pacheco, et. al. Exp. Ther. 257 (1) (1991) 170-183	
	C16	F.M. Casiano, et. al. NIDA Res. Monogr. 105 (1991) 295-6	
	C17	AM630, K. Hosohata, et. al. Life. Sci 61 (1997) 115-118	
	C18	R. Pertwee, et. al., Life Sci. 56 (23-24) (1995) 1949-55	
	C19	LY320135, C.C. Felder, et. al., J. Pharmacol. Exp. Ther. 284, (1) (1998) 291-297 disclosed in WO9602248	
	C20	M. Kanyonyo, et. al., Bioorg. Med. Chem. Lett. 9 (15) (1999) 2233-2236	
	C21	F. Ooms, et. al., J. Med. Chem. 45 (9) (2002) 1748-1756	
Examiner Signature			DATE CONSIDERED

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ² Applicant is to place a check mark here if English language Translation or abstract is attached.

133204